Assessment of a HER2 scoring system for colorectal cancer: Results from a validation study

Modern Pathology

Volumn 28, Issue 11, 2015, Pages 1481-1491

  Valtorta, Emanuele ^a   Martino, Cosimo ^b   Sartore Bianchi, Andrea ^a   Penaullt Llorca, Frédérique ^c   Viale, Giuseppe ^d   Risio, Mauro ^b   Rugge, Massimo ^e   Grigioni, Walter ^f   Bencardino, Katia ^a   Lonardi, Sara ^g   Zagonel, Vittorina ^g   Leone, Francesco ^b   Noe, Johannes ^h   Ciardiello, Fortunato ⁱ   Pinto, Carmine ^f   Labianca, Roberto ^j   Mosconi, Stefania ^j   Graiff, Claudio ^k   Aprile, Giuseppe ^l   Frau, Barbara ^m   Garufi, Carlo ⁿ   Loupakis, Fotios ^o   Racca, Patrizia ^p   Tonini, Giuseppe ^q   Lauricella, Calogero ^a   Veronese, Silvio ^a   Truini, Mauro ^a   Siena, Salvatore ^a,r   Marsoni, Silvia ^b   Gambacorta, Marcello ^a   more..

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c CENTRE JEAN PERRIN   (France)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ SECOND UNIVERSITY OF NAPLES   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k Ospedale di Bolzano   (Italy)

^l SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^m UNIVERSITY OF CAGLIARI   (Italy)

ⁿ REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^o UNIVERSITY HOSPITAL OF PISA   (Italy)

^p CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^q UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^r UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DIAGNOSTIC KIT; DNA PROBE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MOLECULARLY TARGETED THERAPY; PATHOLOGIST; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SILVER IN SITU HYBRIDIZATION; ADULT; AGED; AREA UNDER THE CURVE; CLASSIFICATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENETICS; MALE; MIDDLE AGED; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; STANDARDS; VALIDATION STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PATIENT SELECTION; QUINAZOLINES; RECEPTOR, ERBB-2; ROC CURVE; TRASTUZUMAB;

EID: 84946494571     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.98     Document Type: Article

References (35)

1. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011;135: 55-62.
2. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697.
5. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-337.
6. Song Z, Deng Y, Zhuang K et al. Immunohistochemical results of HER2/neu protein expression assessed by rabbit monoclonal antibodies SP3 and 4B5 in colorectal carcinomas. Int J Clin Exp Pathol 2014;7:4454-4460.
7. Seo AN, Kwak Y, Kim DW et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 2014;9:e98528.
8. Heppner BI, Behrens HM, Balschun K et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014;111:1977-1984.
9. Park DI, Kang MS, Oh SJ et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis 2007;22:491-497.
10. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-523.
11. Oncol JC (ed). Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). Proceedings of the American Society Clinical Oncology Annual Meeting May-4 June 2013. American Society of Clinical Oncology.
12. Tu J, Yu Y, Liu W et al. Significance of human epidermal growth factor receptor 2 expression in colorectal cancer. Exp Ther Med 2015;9:17-24.
13. Ramanathan RK, Hwang JJ, Zamboni WC et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22:858-865.
14. Ooi A, Takehana T, Li X et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17: 895-904.
15. Pavlakis K, Kountourakis P, Stathopoulos E et al. Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol 2007;15:441-445.
16. Kavanagh DO, Chambers G, O'Grady L et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer 2009;9:1.
17. Marx AH, Burandt EC, Choschzick M et al. Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. Hum Pathol 2010;41: 1577-1585.
18. Kruszewski WJ, Rzepko R, Ciesielski M et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers 2010;29:207-212.
19. Blok EJ, Kuppen PJ, van Leeuwen JE et al. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin Med Insights Oncol 2013;7:41-51.
20. Herreros-Villanueva M, Rodrigo M, Claver M et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011;38: 1315-1320.
21. Hofmann M, Stoss O, Shi D et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52:797-805.
22. Rschoff J, Dietel M, Baretton G et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010;457:299-307.
23. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
24. Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568.
25. Gown AM, Goldstein LC, Barry TS et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system. Mod Pathol 2008;21:1271-1277.
26. Jeung J, Patel R, Vila L et al. Quantitation of HER2/neu expression in primary gastroesophageal adenocarcinomas using conventional light microscopy and quantitative image analysis. Arch Pathol Lab Med 2012;136: 610-617.
27. Hanna WM, Hammond E, Taylor CR et al. High concordance betweenimmunohistochemistry and fluorescence in situ hybridization testing for HER2 status inbreast cancer requires a normalized IHC scoring system. Mod Pathol 2008;21:1278-1280. (author reply 80-81).
28. Gomez-Martin C, Plaza JC, Pazo-Cid R et al. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 2013;31: 4445-4452.
29. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31: 3997-4013.
30. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/college of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-256.
31. Scaltriti M, Nuciforo P, Bradbury I et al. High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. Clin Cancer Res 2015;21: 569-576.
32. Guiu S, Gauthier M, Coudert B et al. Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer. Br J Cancer 2010;103: 1335-1342.
33. Gullo G, Bettio D, Torri V et al. Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer. Invest New Drugs 2009;27:179-183.
34. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672.
35. Siena S, Sartore-Bianchi A, Lonardi S et al. Trastuzumab and lapatinib in HER2 amplified metastatic colorectal cancer patients (mCRC): the HERACLES trial. J Clin Oncol 2015;33:Suppl 3508. (oral presentation at ASCO Annual Meeting, Chicago, IL, USA, 28 May-2 June 2015).